Frontage Holdings IPO: Bull/Bear Case DCF Scenarios
Frontage Holdings (1521 HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347 CH)....
633 Views
Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range
Frontage Holdings (1521 HK) has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200...
766 Views
Frontage Holdings (方达控股) IPO: Reasonable Valuation & Quality Cornerstones
Frontage Holdings, a pre-clinical CRO arm of A-share listed Hangzhou Tigermed Consulting (300347 CH), started book building today to raise up to...
793 Views
Viva Biotech (维亚生物) Post-IPO: SELL the Overvalued Incubator
Viva Biotech's IPO was priced at the top end with a very substantial oversubscription. We have highlighted in our earlier note that Viva Biotech's...
659 Views
Frontage Holdings IPO Preview: An Uncertain Transition
Frontage Laboratories Inc (1000371Z HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347...
673 Views